Description

Moreover, the technological advancements in point of care diagnostic devices and introduction of home-based point of care devices are also anticipated to boost the infectious disease point of care diagnostics market. However, reluctance among the patients to change in existing diagnostic practices, stringent regulatory policies, and reimbursement issues might restrain the growth of global infectious disease point of care diagnostics market over the forecast timeframe. Point of care diagnostics refers to the tests carried at site of the patient care to provide the immediate results. These diagnostics improve the disease management and detection. Infectious diseases are caused by various microorganisms such as virus, bacteria, fungi, and parasites. Infectious disease point of care diagnostics reduces the time between disease testing and diagnosis of an infection. Nowadays most of the infectious diseases such as HIV, tuberculosis, influenza, tropical diseases, and sexually transmitted infections are diagnosed by the point of care testing. The major advantages with the point of care testing are reduced in diagnosis time, postoperative care time, improvement in disease outcomes, accuracy in results, and simple methods for diagnosis of the infectious diseases. The global infectious disease point of care diagnostics market is in the flourishing stage as several local and international players are actively involved in the development of infectious disease point of care diagnostic devices. Increase in the prevalence of the deadly infectious disease will drive the growth of the global infectious disease point of care diagnostics market. For instance, according to World Health Organisation, global health observatory (GHO) data, in 2013, approximately 34-38 million people suffered from HIV infection worldwide. Launching of new products, approvals from various regulatory bodies, acquisitions and mergers, partnerships, collaborations, and joint ventures are expected to fuel the growth of global infectious disease point of care diagnostics market over the forecast period. For instance, in January 2015, FDA has approved Alere for its first CLIA waiver for the nucleic acid-based test, Influenza A&B. Further Roche’s CLIA waiver for Cobas Liat System and Strep A. By 2016, many systems received CLIA waivers from FDA including the Xpert Flu/RSV Xc by Cepheid’s. In 2014, in the cardiovascular space, Spartan Biosciences had received approval from Health Care Canada for its genetic test, Spartan RX CYP2C19 system. In 2014, Roche bought point of care molecular testing company iQuum for $275 million and the potential for an additional $175 million in milestone payments

 

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX